nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—CYP1A2—type 2 diabetes mellitus	0.115	0.602	CbGaD
Pazopanib—CYP3A4—type 2 diabetes mellitus	0.076	0.398	CbGaD
Pazopanib—SLCO1B1—Repaglinide—type 2 diabetes mellitus	0.035	0.0829	CbGbCtD
Pazopanib—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.0317	0.075	CbGbCtD
Pazopanib—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.0292	0.0692	CbGbCtD
Pazopanib—SLCO1B1—Valsartan—type 2 diabetes mellitus	0.0258	0.0611	CbGbCtD
Pazopanib—UGT1A1—Losartan—type 2 diabetes mellitus	0.0214	0.0507	CbGbCtD
Pazopanib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0185	0.0439	CbGbCtD
Pazopanib—SLCO1B1—Losartan—type 2 diabetes mellitus	0.0148	0.0351	CbGbCtD
Pazopanib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0148	0.0351	CbGbCtD
Pazopanib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0141	0.0333	CbGbCtD
Pazopanib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0134	0.0317	CbGbCtD
Pazopanib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0129	0.0305	CbGbCtD
Pazopanib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0125	0.0297	CbGbCtD
Pazopanib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0124	0.0293	CbGbCtD
Pazopanib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0119	0.0283	CbGbCtD
Pazopanib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00973	0.0231	CbGbCtD
Pazopanib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00957	0.0227	CbGbCtD
Pazopanib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00907	0.0215	CbGbCtD
Pazopanib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00854	0.0202	CbGbCtD
Pazopanib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00843	0.02	CbGbCtD
Pazopanib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00788	0.0187	CbGbCtD
Pazopanib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00753	0.0179	CbGbCtD
Pazopanib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00751	0.0178	CbGbCtD
Pazopanib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00712	0.0169	CbGbCtD
Pazopanib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00687	0.0163	CbGbCtD
Pazopanib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00647	0.0153	CbGbCtD
Pazopanib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00627	0.0149	CbGbCtD
Pazopanib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00623	0.0148	CbGbCtD
Pazopanib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00621	0.0147	CbGbCtD
Pazopanib—FGF1—corneal epithelium—type 2 diabetes mellitus	0.00609	0.0729	CbGeAlD
Pazopanib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00601	0.0142	CbGbCtD
Pazopanib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00543	0.0129	CbGbCtD
Pazopanib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00486	0.0115	CbGbCtD
Pazopanib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00464	0.011	CbGbCtD
Pazopanib—ABCB1—Losartan—type 2 diabetes mellitus	0.00425	0.0101	CbGbCtD
Pazopanib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00412	0.00975	CbGbCtD
Pazopanib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00395	0.00935	CbGbCtD
Pazopanib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00395	0.00935	CbGbCtD
Pazopanib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00373	0.00884	CbGbCtD
Pazopanib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00278	0.00659	CbGbCtD
Pazopanib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00254	0.00603	CbGbCtD
Pazopanib—BMPR1B—peripheral nervous system—type 2 diabetes mellitus	0.0024	0.0287	CbGeAlD
Pazopanib—PDGFRA—penis—type 2 diabetes mellitus	0.00234	0.028	CbGeAlD
Pazopanib—KDR—hindlimb—type 2 diabetes mellitus	0.00159	0.0191	CbGeAlD
Pazopanib—MAP3K9—islet of Langerhans—type 2 diabetes mellitus	0.00154	0.0185	CbGeAlD
Pazopanib—FGF1—artery—type 2 diabetes mellitus	0.00132	0.0158	CbGeAlD
Pazopanib—FGF1—nerve—type 2 diabetes mellitus	0.00131	0.0157	CbGeAlD
Pazopanib—FLT4—endothelium—type 2 diabetes mellitus	0.00125	0.015	CbGeAlD
Pazopanib—Rilpivirine—CYP1A2—type 2 diabetes mellitus	0.00118	0.602	CrCbGaD
Pazopanib—FLT1—artery—type 2 diabetes mellitus	0.00115	0.0138	CbGeAlD
Pazopanib—FGF1—endothelium—type 2 diabetes mellitus	0.00111	0.0133	CbGeAlD
Pazopanib—SH2B3—islet of Langerhans—type 2 diabetes mellitus	0.00109	0.0131	CbGeAlD
Pazopanib—MAP3K9—pancreas—type 2 diabetes mellitus	0.00109	0.013	CbGeAlD
Pazopanib—KDR—artery—type 2 diabetes mellitus	0.000976	0.0117	CbGeAlD
Pazopanib—FLT1—endothelium—type 2 diabetes mellitus	0.000975	0.0117	CbGeAlD
Pazopanib—SH2B3—retina—type 2 diabetes mellitus	0.000934	0.0112	CbGeAlD
Pazopanib—STK16—islet of Langerhans—type 2 diabetes mellitus	0.000928	0.0111	CbGeAlD
Pazopanib—SH2B3—nephron tubule—type 2 diabetes mellitus	0.000879	0.0105	CbGeAlD
Pazopanib—KDR—endothelium—type 2 diabetes mellitus	0.000824	0.00987	CbGeAlD
Pazopanib—ITK—adipose tissue—type 2 diabetes mellitus	0.000812	0.00973	CbGeAlD
Pazopanib—PI4KB—islet of Langerhans—type 2 diabetes mellitus	0.000808	0.00968	CbGeAlD
Pazopanib—TAOK1—cortex of kidney—type 2 diabetes mellitus	0.000799	0.00957	CbGeAlD
Pazopanib—SH2B3—cardiovascular system—type 2 diabetes mellitus	0.00079	0.00946	CbGeAlD
Pazopanib—Rilpivirine—CYP3A4—type 2 diabetes mellitus	0.000784	0.398	CrCbGaD
Pazopanib—SH2B3—pancreas—type 2 diabetes mellitus	0.000768	0.00919	CbGeAlD
Pazopanib—SH2B3—cortex of kidney—type 2 diabetes mellitus	0.000752	0.00901	CbGeAlD
Pazopanib—TAOK1—adipose tissue—type 2 diabetes mellitus	0.00074	0.00886	CbGeAlD
Pazopanib—RIOK2—nephron tubule—type 2 diabetes mellitus	0.000736	0.00881	CbGeAlD
Pazopanib—KIT—endothelium—type 2 diabetes mellitus	0.00073	0.00874	CbGeAlD
Pazopanib—PIP4K2C—islet of Langerhans—type 2 diabetes mellitus	0.000709	0.00849	CbGeAlD
Pazopanib—SH2B3—adipose tissue—type 2 diabetes mellitus	0.000696	0.00834	CbGeAlD
Pazopanib—MAP3K9—liver—type 2 diabetes mellitus	0.000691	0.00827	CbGeAlD
Pazopanib—PI4KB—nephron tubule—type 2 diabetes mellitus	0.000651	0.00779	CbGeAlD
Pazopanib—FGFR3—kidney—type 2 diabetes mellitus	0.000647	0.00774	CbGeAlD
Pazopanib—FGFR3—cortex of kidney—type 2 diabetes mellitus	0.00063	0.00754	CbGeAlD
Pazopanib—RIOK2—cortex of kidney—type 2 diabetes mellitus	0.00063	0.00754	CbGeAlD
Pazopanib—PIP4K2C—retina—type 2 diabetes mellitus	0.000606	0.00726	CbGeAlD
Pazopanib—STK16—adipose tissue—type 2 diabetes mellitus	0.000592	0.00709	CbGeAlD
Pazopanib—RIOK2—adipose tissue—type 2 diabetes mellitus	0.000583	0.00698	CbGeAlD
Pazopanib—BMPR1B—adipose tissue—type 2 diabetes mellitus	0.000577	0.00691	CbGeAlD
Pazopanib—PI4KB—kidney—type 2 diabetes mellitus	0.000572	0.00685	CbGeAlD
Pazopanib—PIP4K2C—nephron tubule—type 2 diabetes mellitus	0.000571	0.00684	CbGeAlD
Pazopanib—PI4KB—pancreas—type 2 diabetes mellitus	0.000568	0.0068	CbGeAlD
Pazopanib—STK36—cortex of kidney—type 2 diabetes mellitus	0.000566	0.00677	CbGeAlD
Pazopanib—PI4KB—cortex of kidney—type 2 diabetes mellitus	0.000557	0.00667	CbGeAlD
Pazopanib—FLT1—islet of Langerhans—type 2 diabetes mellitus	0.000555	0.00664	CbGeAlD
Pazopanib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000548	0.00656	CbGeAlD
Pazopanib—LIMK2—cortex of kidney—type 2 diabetes mellitus	0.000547	0.00655	CbGeAlD
Pazopanib—FGF1—retina—type 2 diabetes mellitus	0.000542	0.00649	CbGeAlD
Pazopanib—MAP3K2—nephron tubule—type 2 diabetes mellitus	0.000541	0.00648	CbGeAlD
Pazopanib—STK36—adipose tissue—type 2 diabetes mellitus	0.000524	0.00627	CbGeAlD
Pazopanib—TAOK3—islet of Langerhans—type 2 diabetes mellitus	0.000523	0.00626	CbGeAlD
Pazopanib—TAOK1—liver—type 2 diabetes mellitus	0.000519	0.00621	CbGeAlD
Pazopanib—FLT4—cardiovascular system—type 2 diabetes mellitus	0.000516	0.00618	CbGeAlD
Pazopanib—PI4KB—adipose tissue—type 2 diabetes mellitus	0.000516	0.00617	CbGeAlD
Pazopanib—FGF1—nephron tubule—type 2 diabetes mellitus	0.00051	0.00611	CbGeAlD
Pazopanib—LIMK2—adipose tissue—type 2 diabetes mellitus	0.000506	0.00606	CbGeAlD
Pazopanib—PIP4K2C—pancreas—type 2 diabetes mellitus	0.000499	0.00597	CbGeAlD
Pazopanib—FLT4—cortex of kidney—type 2 diabetes mellitus	0.000492	0.00589	CbGeAlD
Pazopanib—PIP4K2C—cortex of kidney—type 2 diabetes mellitus	0.000489	0.00585	CbGeAlD
Pazopanib—SH2B3—liver—type 2 diabetes mellitus	0.000488	0.00585	CbGeAlD
Pazopanib—FGFR1—cortex of kidney—type 2 diabetes mellitus	0.000485	0.00581	CbGeAlD
Pazopanib—FLT1—retina—type 2 diabetes mellitus	0.000474	0.00568	CbGeAlD
Pazopanib—FGF1—cardiovascular system—type 2 diabetes mellitus	0.000458	0.00549	CbGeAlD
Pazopanib—FLT4—adipose tissue—type 2 diabetes mellitus	0.000455	0.00545	CbGeAlD
Pazopanib—PIP4K2C—adipose tissue—type 2 diabetes mellitus	0.000452	0.00542	CbGeAlD
Pazopanib—FGFR1—adipose tissue—type 2 diabetes mellitus	0.000449	0.00537	CbGeAlD
Pazopanib—FGF1—kidney—type 2 diabetes mellitus	0.000448	0.00537	CbGeAlD
Pazopanib—TAOK3—retina—type 2 diabetes mellitus	0.000447	0.00535	CbGeAlD
Pazopanib—FLT1—nephron tubule—type 2 diabetes mellitus	0.000447	0.00535	CbGeAlD
Pazopanib—FGF1—cortex of kidney—type 2 diabetes mellitus	0.000437	0.00523	CbGeAlD
Pazopanib—FGFR2—cardiovascular system—type 2 diabetes mellitus	0.000433	0.00518	CbGeAlD
Pazopanib—MAP3K2—adipose tissue—type 2 diabetes mellitus	0.000429	0.00513	CbGeAlD
Pazopanib—FGFR2—kidney—type 2 diabetes mellitus	0.000423	0.00507	CbGeAlD
Pazopanib—TAOK3—nephron tubule—type 2 diabetes mellitus	0.000421	0.00504	CbGeAlD
Pazopanib—STK16—liver—type 2 diabetes mellitus	0.000415	0.00497	CbGeAlD
Pazopanib—LYN—liver—type 2 diabetes mellitus	0.000411	0.00492	CbGeAlD
Pazopanib—RIOK2—liver—type 2 diabetes mellitus	0.000409	0.00489	CbGeAlD
Pazopanib—FGFR3—liver—type 2 diabetes mellitus	0.000409	0.00489	CbGeAlD
Pazopanib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000406	0.00486	CbGeAlD
Pazopanib—FGF1—adipose tissue—type 2 diabetes mellitus	0.000404	0.00484	CbGeAlD
Pazopanib—LCK—adipose tissue—type 2 diabetes mellitus	0.000402	0.00481	CbGeAlD
Pazopanib—FLT1—cardiovascular system—type 2 diabetes mellitus	0.000401	0.0048	CbGeAlD
Pazopanib—KDR—retina—type 2 diabetes mellitus	0.000401	0.0048	CbGeAlD
Pazopanib—FLT1—kidney—type 2 diabetes mellitus	0.000392	0.0047	CbGeAlD
Pazopanib—FLT1—pancreas—type 2 diabetes mellitus	0.00039	0.00467	CbGeAlD
Pazopanib—FLT1—cortex of kidney—type 2 diabetes mellitus	0.000382	0.00458	CbGeAlD
Pazopanib—FGFR2—adipose tissue—type 2 diabetes mellitus	0.000382	0.00457	CbGeAlD
Pazopanib—STK10—cardiovascular system—type 2 diabetes mellitus	0.00038	0.00455	CbGeAlD
Pazopanib—TAOK3—cardiovascular system—type 2 diabetes mellitus	0.000378	0.00453	CbGeAlD
Pazopanib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.000378	0.00452	CbGeAlD
Pazopanib—KDR—nephron tubule—type 2 diabetes mellitus	0.000377	0.00452	CbGeAlD
Pazopanib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000376	0.0045	CbGeAlD
Pazopanib—STK10—kidney—type 2 diabetes mellitus	0.000371	0.00445	CbGeAlD
Pazopanib—TAOK3—kidney—type 2 diabetes mellitus	0.00037	0.00443	CbGeAlD
Pazopanib—TAOK3—pancreas—type 2 diabetes mellitus	0.000368	0.0044	CbGeAlD
Pazopanib—STK36—liver—type 2 diabetes mellitus	0.000367	0.0044	CbGeAlD
Pazopanib—PI4KB—liver—type 2 diabetes mellitus	0.000362	0.00433	CbGeAlD
Pazopanib—TAOK3—cortex of kidney—type 2 diabetes mellitus	0.00036	0.00432	CbGeAlD
Pazopanib—LIMK2—liver—type 2 diabetes mellitus	0.000355	0.00425	CbGeAlD
Pazopanib—FLT1—adipose tissue—type 2 diabetes mellitus	0.000354	0.00423	CbGeAlD
Pazopanib—UGT1A1—kidney—type 2 diabetes mellitus	0.000351	0.0042	CbGeAlD
Pazopanib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.00035	0.00419	CbGeAlD
Pazopanib—KDR—cardiovascular system—type 2 diabetes mellitus	0.000339	0.00406	CbGeAlD
Pazopanib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000339	0.00406	CbGeAlD
Pazopanib—STK10—adipose tissue—type 2 diabetes mellitus	0.000335	0.00401	CbGeAlD
Pazopanib—KIT—nephron tubule—type 2 diabetes mellitus	0.000334	0.00401	CbGeAlD
Pazopanib—TAOK3—adipose tissue—type 2 diabetes mellitus	0.000333	0.00399	CbGeAlD
Pazopanib—KDR—kidney—type 2 diabetes mellitus	0.000332	0.00397	CbGeAlD
Pazopanib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000331	0.00397	CbGeAlD
Pazopanib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000331	0.00396	CbGeAlD
Pazopanib—KDR—cortex of kidney—type 2 diabetes mellitus	0.000323	0.00387	CbGeAlD
Pazopanib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000323	0.00387	CbGeAlD
Pazopanib—FLT4—liver—type 2 diabetes mellitus	0.000319	0.00382	CbGeAlD
Pazopanib—PIP4K2C—liver—type 2 diabetes mellitus	0.000317	0.0038	CbGeAlD
Pazopanib—FGFR1—liver—type 2 diabetes mellitus	0.000315	0.00377	CbGeAlD
Pazopanib—MAP3K2—liver—type 2 diabetes mellitus	0.000301	0.0036	CbGeAlD
Pazopanib—KIT—cardiovascular system—type 2 diabetes mellitus	0.0003	0.0036	CbGeAlD
Pazopanib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000299	0.00358	CbGeAlD
Pazopanib—KDR—adipose tissue—type 2 diabetes mellitus	0.000299	0.00358	CbGeAlD
Pazopanib—KIT—kidney—type 2 diabetes mellitus	0.000294	0.00352	CbGeAlD
Pazopanib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000293	0.00351	CbGeAlD
Pazopanib—KIT—pancreas—type 2 diabetes mellitus	0.000292	0.0035	CbGeAlD
Pazopanib—SLCO1B1—kidney—type 2 diabetes mellitus	0.000292	0.0035	CbGeAlD
Pazopanib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000292	0.00349	CbGeAlD
Pazopanib—PDGFRB—kidney—type 2 diabetes mellitus	0.000287	0.00344	CbGeAlD
Pazopanib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000286	0.00343	CbGeAlD
Pazopanib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000285	0.00342	CbGeAlD
Pazopanib—FGF1—liver—type 2 diabetes mellitus	0.000283	0.00339	CbGeAlD
Pazopanib—LCK—liver—type 2 diabetes mellitus	0.000282	0.00337	CbGeAlD
Pazopanib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.00028	0.00335	CbGeAlD
Pazopanib—FGFR2—liver—type 2 diabetes mellitus	0.000268	0.0032	CbGeAlD
Pazopanib—KIT—adipose tissue—type 2 diabetes mellitus	0.000265	0.00317	CbGeAlD
Pazopanib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000259	0.0031	CbGeAlD
Pazopanib—FLT1—liver—type 2 diabetes mellitus	0.000248	0.00297	CbGeAlD
Pazopanib—STK10—liver—type 2 diabetes mellitus	0.000235	0.00281	CbGeAlD
Pazopanib—TAOK3—liver—type 2 diabetes mellitus	0.000234	0.0028	CbGeAlD
Pazopanib—PDGFRA—liver—type 2 diabetes mellitus	0.000232	0.00278	CbGeAlD
Pazopanib—UGT1A1—liver—type 2 diabetes mellitus	0.000222	0.00265	CbGeAlD
Pazopanib—MAP2K5—liver—type 2 diabetes mellitus	0.00021	0.00251	CbGeAlD
Pazopanib—KDR—liver—type 2 diabetes mellitus	0.00021	0.00251	CbGeAlD
Pazopanib—CSF1R—liver—type 2 diabetes mellitus	0.000205	0.00245	CbGeAlD
Pazopanib—KIT—liver—type 2 diabetes mellitus	0.000186	0.00222	CbGeAlD
Pazopanib—SLCO1B1—liver—type 2 diabetes mellitus	0.000184	0.00221	CbGeAlD
Pazopanib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000184	0.0022	CbGeAlD
Pazopanib—PDGFRB—liver—type 2 diabetes mellitus	0.000181	0.00217	CbGeAlD
Pazopanib—CYP2C8—kidney—type 2 diabetes mellitus	0.000166	0.00199	CbGeAlD
Pazopanib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000145	0.00174	CbGeAlD
Pazopanib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000112	0.00135	CbGeAlD
Pazopanib—CYP3A4—kidney—type 2 diabetes mellitus	0.000112	0.00135	CbGeAlD
Pazopanib—CYP2D6—kidney—type 2 diabetes mellitus	0.000111	0.00132	CbGeAlD
Pazopanib—CYP2C8—liver—type 2 diabetes mellitus	0.000105	0.00126	CbGeAlD
Pazopanib—ABCG2—liver—type 2 diabetes mellitus	0.000102	0.00122	CbGeAlD
Pazopanib—CYP1A2—liver—type 2 diabetes mellitus	9.82e-05	0.00118	CbGeAlD
Pazopanib—ABCB1—retina—type 2 diabetes mellitus	9.61e-05	0.00115	CbGeAlD
Pazopanib—ABCB1—nephron tubule—type 2 diabetes mellitus	9.05e-05	0.00108	CbGeAlD
Pazopanib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	8.85e-05	0.000557	CcSEcCtD
Pazopanib—Paraesthesia—Gliclazide—type 2 diabetes mellitus	8.84e-05	0.000556	CcSEcCtD
Pazopanib—Flatulence—Losartan—type 2 diabetes mellitus	8.83e-05	0.000556	CcSEcCtD
Pazopanib—Anaemia—Irbesartan—type 2 diabetes mellitus	8.8e-05	0.000554	CcSEcCtD
Pazopanib—Dizziness—Glimepiride—type 2 diabetes mellitus	8.79e-05	0.000553	CcSEcCtD
Pazopanib—Skin disorder—Valsartan—type 2 diabetes mellitus	8.78e-05	0.000553	CcSEcCtD
Pazopanib—Dysgeusia—Losartan—type 2 diabetes mellitus	8.78e-05	0.000552	CcSEcCtD
Pazopanib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	8.78e-05	0.000552	CcSEcCtD
Pazopanib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	8.76e-05	0.000551	CcSEcCtD
Pazopanib—Dizziness—Sitagliptin—type 2 diabetes mellitus	8.76e-05	0.000551	CcSEcCtD
Pazopanib—Somnolence—Gliclazide—type 2 diabetes mellitus	8.75e-05	0.000551	CcSEcCtD
Pazopanib—Hypertension—Metformin—type 2 diabetes mellitus	8.71e-05	0.000548	CcSEcCtD
Pazopanib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	8.7e-05	0.000547	CcSEcCtD
Pazopanib—Skin disorder—Orlistat—type 2 diabetes mellitus	8.68e-05	0.000546	CcSEcCtD
Pazopanib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	8.67e-05	0.000546	CcSEcCtD
Pazopanib—Abdominal pain—Glyburide—type 2 diabetes mellitus	8.67e-05	0.000545	CcSEcCtD
Pazopanib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	8.66e-05	0.000545	CcSEcCtD
Pazopanib—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	8.64e-05	0.000544	CcSEcCtD
Pazopanib—Anorexia—Valsartan—type 2 diabetes mellitus	8.62e-05	0.000542	CcSEcCtD
Pazopanib—Muscle spasms—Losartan—type 2 diabetes mellitus	8.62e-05	0.000542	CcSEcCtD
Pazopanib—Asthenia—Bromocriptine—type 2 diabetes mellitus	8.6e-05	0.000541	CcSEcCtD
Pazopanib—Myalgia—Metformin—type 2 diabetes mellitus	8.59e-05	0.000541	CcSEcCtD
Pazopanib—Chest pain—Metformin—type 2 diabetes mellitus	8.59e-05	0.000541	CcSEcCtD
Pazopanib—Headache—Pioglitazone—type 2 diabetes mellitus	8.55e-05	0.000538	CcSEcCtD
Pazopanib—Syncope—Irbesartan—type 2 diabetes mellitus	8.54e-05	0.000537	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	8.53e-05	0.000537	CcSEcCtD
Pazopanib—Leukopenia—Irbesartan—type 2 diabetes mellitus	8.52e-05	0.000536	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	8.5e-05	0.000535	CcSEcCtD
Pazopanib—Fatigue—Gliclazide—type 2 diabetes mellitus	8.49e-05	0.000534	CcSEcCtD
Pazopanib—Nausea—Glipizide—type 2 diabetes mellitus	8.46e-05	0.000532	CcSEcCtD
Pazopanib—Vomiting—Glimepiride—type 2 diabetes mellitus	8.45e-05	0.000532	CcSEcCtD
Pazopanib—Vision blurred—Losartan—type 2 diabetes mellitus	8.45e-05	0.000531	CcSEcCtD
Pazopanib—Vomiting—Sitagliptin—type 2 diabetes mellitus	8.43e-05	0.00053	CcSEcCtD
Pazopanib—Pain—Gliclazide—type 2 diabetes mellitus	8.42e-05	0.00053	CcSEcCtD
Pazopanib—Rash—Glimepiride—type 2 diabetes mellitus	8.38e-05	0.000527	CcSEcCtD
Pazopanib—Dermatitis—Glimepiride—type 2 diabetes mellitus	8.37e-05	0.000527	CcSEcCtD
Pazopanib—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	8.37e-05	0.000527	CcSEcCtD
Pazopanib—Rash—Sitagliptin—type 2 diabetes mellitus	8.35e-05	0.000526	CcSEcCtD
Pazopanib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	8.35e-05	0.000525	CcSEcCtD
Pazopanib—Headache—Glimepiride—type 2 diabetes mellitus	8.33e-05	0.000524	CcSEcCtD
Pazopanib—Cough—Irbesartan—type 2 diabetes mellitus	8.31e-05	0.000523	CcSEcCtD
Pazopanib—Headache—Sitagliptin—type 2 diabetes mellitus	8.3e-05	0.000522	CcSEcCtD
Pazopanib—Anaemia—Losartan—type 2 diabetes mellitus	8.28e-05	0.000521	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	8.24e-05	0.000518	CcSEcCtD
Pazopanib—Oedema—Metformin—type 2 diabetes mellitus	8.24e-05	0.000518	CcSEcCtD
Pazopanib—Hypertension—Irbesartan—type 2 diabetes mellitus	8.22e-05	0.000517	CcSEcCtD
Pazopanib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	8.2e-05	0.000516	CcSEcCtD
Pazopanib—Flushing—Ramipril—type 2 diabetes mellitus	8.19e-05	0.000515	CcSEcCtD
Pazopanib—Infection—Metformin—type 2 diabetes mellitus	8.18e-05	0.000515	CcSEcCtD
Pazopanib—Insomnia—Valsartan—type 2 diabetes mellitus	8.18e-05	0.000515	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	8.14e-05	0.000512	CcSEcCtD
Pazopanib—ABCB1—cardiovascular system—type 2 diabetes mellitus	8.13e-05	0.000974	CbGeAlD
Pazopanib—Paraesthesia—Valsartan—type 2 diabetes mellitus	8.12e-05	0.000511	CcSEcCtD
Pazopanib—Chest pain—Irbesartan—type 2 diabetes mellitus	8.11e-05	0.00051	CcSEcCtD
Pazopanib—Myalgia—Irbesartan—type 2 diabetes mellitus	8.11e-05	0.00051	CcSEcCtD
Pazopanib—Arthralgia—Irbesartan—type 2 diabetes mellitus	8.11e-05	0.00051	CcSEcCtD
Pazopanib—Shock—Metformin—type 2 diabetes mellitus	8.1e-05	0.00051	CcSEcCtD
Pazopanib—Insomnia—Orlistat—type 2 diabetes mellitus	8.08e-05	0.000509	CcSEcCtD
Pazopanib—Nervous system disorder—Metformin—type 2 diabetes mellitus	8.08e-05	0.000508	CcSEcCtD
Pazopanib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	8.06e-05	0.000507	CcSEcCtD
Pazopanib—Dyspnoea—Valsartan—type 2 diabetes mellitus	8.06e-05	0.000507	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	8.05e-05	0.000507	CcSEcCtD
Pazopanib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	8.05e-05	0.000506	CcSEcCtD
Pazopanib—Somnolence—Valsartan—type 2 diabetes mellitus	8.04e-05	0.000506	CcSEcCtD
Pazopanib—Syncope—Losartan—type 2 diabetes mellitus	8.04e-05	0.000506	CcSEcCtD
Pazopanib—Paraesthesia—Orlistat—type 2 diabetes mellitus	8.02e-05	0.000505	CcSEcCtD
Pazopanib—Leukopenia—Losartan—type 2 diabetes mellitus	8.02e-05	0.000505	CcSEcCtD
Pazopanib—Skin disorder—Metformin—type 2 diabetes mellitus	8e-05	0.000503	CcSEcCtD
Pazopanib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	7.96e-05	0.000501	CcSEcCtD
Pazopanib—Dyspepsia—Valsartan—type 2 diabetes mellitus	7.96e-05	0.000501	CcSEcCtD
Pazopanib—ABCB1—kidney—type 2 diabetes mellitus	7.96e-05	0.000953	CbGeAlD
Pazopanib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	7.96e-05	0.000501	CcSEcCtD
Pazopanib—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.93e-05	0.000499	CcSEcCtD
Pazopanib—Dry mouth—Irbesartan—type 2 diabetes mellitus	7.93e-05	0.000499	CcSEcCtD
Pazopanib—ABCB1—pancreas—type 2 diabetes mellitus	7.9e-05	0.000947	CbGeAlD
Pazopanib—Nausea—Glimepiride—type 2 diabetes mellitus	7.9e-05	0.000497	CcSEcCtD
Pazopanib—Loss of consciousness—Losartan—type 2 diabetes mellitus	7.88e-05	0.000496	CcSEcCtD
Pazopanib—Nausea—Sitagliptin—type 2 diabetes mellitus	7.87e-05	0.000495	CcSEcCtD
Pazopanib—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.87e-05	0.000495	CcSEcCtD
Pazopanib—Asthenia—Glyburide—type 2 diabetes mellitus	7.87e-05	0.000495	CcSEcCtD
Pazopanib—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.86e-05	0.000495	CcSEcCtD
Pazopanib—Anorexia—Metformin—type 2 diabetes mellitus	7.85e-05	0.000494	CcSEcCtD
Pazopanib—Cough—Losartan—type 2 diabetes mellitus	7.82e-05	0.000492	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.81e-05	0.000491	CcSEcCtD
Pazopanib—Alopecia—Ramipril—type 2 diabetes mellitus	7.8e-05	0.000491	CcSEcCtD
Pazopanib—Fatigue—Valsartan—type 2 diabetes mellitus	7.8e-05	0.000491	CcSEcCtD
Pazopanib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	7.78e-05	0.00049	CcSEcCtD
Pazopanib—Oedema—Irbesartan—type 2 diabetes mellitus	7.77e-05	0.000489	CcSEcCtD
Pazopanib—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.77e-05	0.000489	CcSEcCtD
Pazopanib—Pruritus—Glyburide—type 2 diabetes mellitus	7.76e-05	0.000488	CcSEcCtD
Pazopanib—ABCB1—cortex of kidney—type 2 diabetes mellitus	7.75e-05	0.000928	CbGeAlD
Pazopanib—Mental disorder—Ramipril—type 2 diabetes mellitus	7.73e-05	0.000487	CcSEcCtD
Pazopanib—Infection—Irbesartan—type 2 diabetes mellitus	7.72e-05	0.000486	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.72e-05	0.000485	CcSEcCtD
Pazopanib—Fatigue—Orlistat—type 2 diabetes mellitus	7.7e-05	0.000485	CcSEcCtD
Pazopanib—Erythema—Ramipril—type 2 diabetes mellitus	7.68e-05	0.000484	CcSEcCtD
Pazopanib—Malnutrition—Ramipril—type 2 diabetes mellitus	7.68e-05	0.000484	CcSEcCtD
Pazopanib—Shock—Irbesartan—type 2 diabetes mellitus	7.65e-05	0.000481	CcSEcCtD
Pazopanib—Pain—Orlistat—type 2 diabetes mellitus	7.64e-05	0.000481	CcSEcCtD
Pazopanib—Chest pain—Losartan—type 2 diabetes mellitus	7.63e-05	0.00048	CcSEcCtD
Pazopanib—Arthralgia—Losartan—type 2 diabetes mellitus	7.63e-05	0.00048	CcSEcCtD
Pazopanib—Myalgia—Losartan—type 2 diabetes mellitus	7.63e-05	0.00048	CcSEcCtD
Pazopanib—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.62e-05	0.00048	CcSEcCtD
Pazopanib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7.62e-05	0.00048	CcSEcCtD
Pazopanib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000479	CcSEcCtD
Pazopanib—Rash—Bromocriptine—type 2 diabetes mellitus	7.56e-05	0.000476	CcSEcCtD
Pazopanib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.55e-05	0.000475	CcSEcCtD
Pazopanib—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.55e-05	0.000475	CcSEcCtD
Pazopanib—Dysgeusia—Ramipril—type 2 diabetes mellitus	7.53e-05	0.000473	CcSEcCtD
Pazopanib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.51e-05	0.000473	CcSEcCtD
Pazopanib—Headache—Bromocriptine—type 2 diabetes mellitus	7.51e-05	0.000473	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	7.5e-05	0.000472	CcSEcCtD
Pazopanib—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.5e-05	0.000472	CcSEcCtD
Pazopanib—Dry mouth—Losartan—type 2 diabetes mellitus	7.46e-05	0.00047	CcSEcCtD
Pazopanib—Anorexia—Irbesartan—type 2 diabetes mellitus	7.41e-05	0.000466	CcSEcCtD
Pazopanib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000465	CcSEcCtD
Pazopanib—Paraesthesia—Metformin—type 2 diabetes mellitus	7.4e-05	0.000465	CcSEcCtD
Pazopanib—Muscle spasms—Ramipril—type 2 diabetes mellitus	7.39e-05	0.000465	CcSEcCtD
Pazopanib—Dyspnoea—Metformin—type 2 diabetes mellitus	7.34e-05	0.000462	CcSEcCtD
Pazopanib—Somnolence—Metformin—type 2 diabetes mellitus	7.32e-05	0.000461	CcSEcCtD
Pazopanib—Oedema—Losartan—type 2 diabetes mellitus	7.31e-05	0.00046	CcSEcCtD
Pazopanib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	7.31e-05	0.00046	CcSEcCtD
Pazopanib—Infection—Losartan—type 2 diabetes mellitus	7.27e-05	0.000457	CcSEcCtD
Pazopanib—Dyspepsia—Metformin—type 2 diabetes mellitus	7.25e-05	0.000456	CcSEcCtD
Pazopanib—Shock—Losartan—type 2 diabetes mellitus	7.2e-05	0.000453	CcSEcCtD
Pazopanib—Nervous system disorder—Losartan—type 2 diabetes mellitus	7.17e-05	0.000451	CcSEcCtD
Pazopanib—ABCB1—adipose tissue—type 2 diabetes mellitus	7.17e-05	0.000859	CbGeAlD
Pazopanib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	7.16e-05	0.000451	CcSEcCtD
Pazopanib—Decreased appetite—Metformin—type 2 diabetes mellitus	7.16e-05	0.00045	CcSEcCtD
Pazopanib—Abdominal pain—Valsartan—type 2 diabetes mellitus	7.15e-05	0.00045	CcSEcCtD
Pazopanib—Nausea—Bromocriptine—type 2 diabetes mellitus	7.12e-05	0.000448	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	7.11e-05	0.000447	CcSEcCtD
Pazopanib—CYP3A4—liver—type 2 diabetes mellitus	7.11e-05	0.000851	CbGeAlD
Pazopanib—Fatigue—Metformin—type 2 diabetes mellitus	7.1e-05	0.000447	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.000446	CcSEcCtD
Pazopanib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	7.07e-05	0.000445	CcSEcCtD
Pazopanib—Abdominal pain—Orlistat—type 2 diabetes mellitus	7.06e-05	0.000444	CcSEcCtD
Pazopanib—Asthenia—Gliclazide—type 2 diabetes mellitus	7.06e-05	0.000444	CcSEcCtD
Pazopanib—CYP2D6—liver—type 2 diabetes mellitus	6.99e-05	0.000837	CbGeAlD
Pazopanib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.98e-05	0.000439	CcSEcCtD
Pazopanib—Anorexia—Losartan—type 2 diabetes mellitus	6.97e-05	0.000439	CcSEcCtD
Pazopanib—Vomiting—Glyburide—type 2 diabetes mellitus	6.97e-05	0.000439	CcSEcCtD
Pazopanib—Pruritus—Gliclazide—type 2 diabetes mellitus	6.96e-05	0.000438	CcSEcCtD
Pazopanib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.93e-05	0.000436	CcSEcCtD
Pazopanib—Rash—Glyburide—type 2 diabetes mellitus	6.91e-05	0.000435	CcSEcCtD
Pazopanib—Somnolence—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.000435	CcSEcCtD
Pazopanib—Dermatitis—Glyburide—type 2 diabetes mellitus	6.91e-05	0.000434	CcSEcCtD
Pazopanib—Syncope—Ramipril—type 2 diabetes mellitus	6.89e-05	0.000434	CcSEcCtD
Pazopanib—Leukopenia—Ramipril—type 2 diabetes mellitus	6.88e-05	0.000433	CcSEcCtD
Pazopanib—Headache—Glyburide—type 2 diabetes mellitus	6.87e-05	0.000432	CcSEcCtD
Pazopanib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.84e-05	0.00043	CcSEcCtD
Pazopanib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.76e-05	0.000425	CcSEcCtD
Pazopanib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	6.75e-05	0.000425	CcSEcCtD
Pazopanib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.74e-05	0.000424	CcSEcCtD
Pazopanib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.73e-05	0.000424	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.71e-05	0.000422	CcSEcCtD
Pazopanib—Cough—Ramipril—type 2 diabetes mellitus	6.71e-05	0.000422	CcSEcCtD
Pazopanib—Fatigue—Irbesartan—type 2 diabetes mellitus	6.7e-05	0.000422	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.66e-05	0.000419	CcSEcCtD
Pazopanib—Pain—Irbesartan—type 2 diabetes mellitus	6.65e-05	0.000418	CcSEcCtD
Pazopanib—Insomnia—Losartan—type 2 diabetes mellitus	6.62e-05	0.000416	CcSEcCtD
Pazopanib—Paraesthesia—Losartan—type 2 diabetes mellitus	6.57e-05	0.000413	CcSEcCtD
Pazopanib—Arthralgia—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000412	CcSEcCtD
Pazopanib—Chest pain—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000412	CcSEcCtD
Pazopanib—Myalgia—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000412	CcSEcCtD
Pazopanib—Dyspnoea—Losartan—type 2 diabetes mellitus	6.52e-05	0.00041	CcSEcCtD
Pazopanib—Nausea—Glyburide—type 2 diabetes mellitus	6.51e-05	0.00041	CcSEcCtD
Pazopanib—Abdominal pain—Metformin—type 2 diabetes mellitus	6.51e-05	0.00041	CcSEcCtD
Pazopanib—Dizziness—Gliclazide—type 2 diabetes mellitus	6.51e-05	0.00041	CcSEcCtD
Pazopanib—Somnolence—Losartan—type 2 diabetes mellitus	6.5e-05	0.000409	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	6.5e-05	0.000409	CcSEcCtD
Pazopanib—Asthenia—Valsartan—type 2 diabetes mellitus	6.49e-05	0.000408	CcSEcCtD
Pazopanib—Dyspepsia—Losartan—type 2 diabetes mellitus	6.44e-05	0.000405	CcSEcCtD
Pazopanib—Asthenia—Orlistat—type 2 diabetes mellitus	6.41e-05	0.000403	CcSEcCtD
Pazopanib—Pruritus—Valsartan—type 2 diabetes mellitus	6.4e-05	0.000403	CcSEcCtD
Pazopanib—Dry mouth—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000403	CcSEcCtD
Pazopanib—Decreased appetite—Losartan—type 2 diabetes mellitus	6.36e-05	0.0004	CcSEcCtD
Pazopanib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.0004	CcSEcCtD
Pazopanib—Pruritus—Orlistat—type 2 diabetes mellitus	6.32e-05	0.000398	CcSEcCtD
Pazopanib—Fatigue—Losartan—type 2 diabetes mellitus	6.31e-05	0.000397	CcSEcCtD
Pazopanib—Oedema—Ramipril—type 2 diabetes mellitus	6.27e-05	0.000395	CcSEcCtD
Pazopanib—Vomiting—Gliclazide—type 2 diabetes mellitus	6.26e-05	0.000394	CcSEcCtD
Pazopanib—Pain—Losartan—type 2 diabetes mellitus	6.25e-05	0.000394	CcSEcCtD
Pazopanib—Rash—Gliclazide—type 2 diabetes mellitus	6.21e-05	0.000391	CcSEcCtD
Pazopanib—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.2e-05	0.00039	CcSEcCtD
Pazopanib—Diarrhoea—Valsartan—type 2 diabetes mellitus	6.19e-05	0.000389	CcSEcCtD
Pazopanib—Shock—Ramipril—type 2 diabetes mellitus	6.17e-05	0.000388	CcSEcCtD
Pazopanib—Headache—Gliclazide—type 2 diabetes mellitus	6.17e-05	0.000388	CcSEcCtD
Pazopanib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	6.15e-05	0.000387	CcSEcCtD
Pazopanib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	6.14e-05	0.000387	CcSEcCtD
Pazopanib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000386	CcSEcCtD
Pazopanib—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.11e-05	0.000385	CcSEcCtD
Pazopanib—Skin disorder—Ramipril—type 2 diabetes mellitus	6.09e-05	0.000383	CcSEcCtD
Pazopanib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000381	CcSEcCtD
Pazopanib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.98e-05	0.000376	CcSEcCtD
Pazopanib—Dizziness—Valsartan—type 2 diabetes mellitus	5.98e-05	0.000376	CcSEcCtD
Pazopanib—Anorexia—Ramipril—type 2 diabetes mellitus	5.98e-05	0.000376	CcSEcCtD
Pazopanib—Dizziness—Orlistat—type 2 diabetes mellitus	5.91e-05	0.000372	CcSEcCtD
Pazopanib—Asthenia—Metformin—type 2 diabetes mellitus	5.91e-05	0.000372	CcSEcCtD
Pazopanib—Nausea—Gliclazide—type 2 diabetes mellitus	5.85e-05	0.000368	CcSEcCtD
Pazopanib—Pruritus—Metformin—type 2 diabetes mellitus	5.83e-05	0.000367	CcSEcCtD
Pazopanib—Abdominal pain—Losartan—type 2 diabetes mellitus	5.78e-05	0.000364	CcSEcCtD
Pazopanib—Vomiting—Valsartan—type 2 diabetes mellitus	5.75e-05	0.000362	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.71e-05	0.00036	CcSEcCtD
Pazopanib—Rash—Valsartan—type 2 diabetes mellitus	5.7e-05	0.000359	CcSEcCtD
Pazopanib—Dermatitis—Valsartan—type 2 diabetes mellitus	5.7e-05	0.000358	CcSEcCtD
Pazopanib—Vomiting—Orlistat—type 2 diabetes mellitus	5.68e-05	0.000358	CcSEcCtD
Pazopanib—Insomnia—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000357	CcSEcCtD
Pazopanib—Headache—Valsartan—type 2 diabetes mellitus	5.67e-05	0.000356	CcSEcCtD
Pazopanib—Diarrhoea—Metformin—type 2 diabetes mellitus	5.64e-05	0.000355	CcSEcCtD
Pazopanib—Rash—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000355	CcSEcCtD
Pazopanib—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000354	CcSEcCtD
Pazopanib—Dermatitis—Orlistat—type 2 diabetes mellitus	5.63e-05	0.000354	CcSEcCtD
Pazopanib—Headache—Orlistat—type 2 diabetes mellitus	5.6e-05	0.000352	CcSEcCtD
Pazopanib—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000352	CcSEcCtD
Pazopanib—Asthenia—Irbesartan—type 2 diabetes mellitus	5.58e-05	0.000351	CcSEcCtD
Pazopanib—Somnolence—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000351	CcSEcCtD
Pazopanib—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.52e-05	0.000347	CcSEcCtD
Pazopanib—Pruritus—Irbesartan—type 2 diabetes mellitus	5.5e-05	0.000346	CcSEcCtD
Pazopanib—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.45e-05	0.000343	CcSEcCtD
Pazopanib—Dizziness—Metformin—type 2 diabetes mellitus	5.45e-05	0.000343	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	5.41e-05	0.000341	CcSEcCtD
Pazopanib—Fatigue—Ramipril—type 2 diabetes mellitus	5.41e-05	0.00034	CcSEcCtD
Pazopanib—Nausea—Valsartan—type 2 diabetes mellitus	5.37e-05	0.000338	CcSEcCtD
Pazopanib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.32e-05	0.000335	CcSEcCtD
Pazopanib—Nausea—Orlistat—type 2 diabetes mellitus	5.31e-05	0.000334	CcSEcCtD
Pazopanib—Asthenia—Losartan—type 2 diabetes mellitus	5.25e-05	0.00033	CcSEcCtD
Pazopanib—Vomiting—Metformin—type 2 diabetes mellitus	5.24e-05	0.000329	CcSEcCtD
Pazopanib—Rash—Metformin—type 2 diabetes mellitus	5.19e-05	0.000327	CcSEcCtD
Pazopanib—Dermatitis—Metformin—type 2 diabetes mellitus	5.19e-05	0.000326	CcSEcCtD
Pazopanib—Pruritus—Losartan—type 2 diabetes mellitus	5.17e-05	0.000326	CcSEcCtD
Pazopanib—Headache—Metformin—type 2 diabetes mellitus	5.16e-05	0.000325	CcSEcCtD
Pazopanib—Dizziness—Irbesartan—type 2 diabetes mellitus	5.14e-05	0.000323	CcSEcCtD
Pazopanib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000323	CcSEcCtD
Pazopanib—ABCB1—liver—type 2 diabetes mellitus	5.03e-05	0.000602	CbGeAlD
Pazopanib—Diarrhoea—Losartan—type 2 diabetes mellitus	5e-05	0.000315	CcSEcCtD
Pazopanib—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.96e-05	0.000312	CcSEcCtD
Pazopanib—Vomiting—Irbesartan—type 2 diabetes mellitus	4.94e-05	0.000311	CcSEcCtD
Pazopanib—Rash—Irbesartan—type 2 diabetes mellitus	4.9e-05	0.000308	CcSEcCtD
Pazopanib—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.9e-05	0.000308	CcSEcCtD
Pazopanib—Nausea—Metformin—type 2 diabetes mellitus	4.89e-05	0.000308	CcSEcCtD
Pazopanib—Headache—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000306	CcSEcCtD
Pazopanib—Dizziness—Losartan—type 2 diabetes mellitus	4.84e-05	0.000304	CcSEcCtD
Pazopanib—Vomiting—Losartan—type 2 diabetes mellitus	4.65e-05	0.000293	CcSEcCtD
Pazopanib—Nausea—Irbesartan—type 2 diabetes mellitus	4.62e-05	0.00029	CcSEcCtD
Pazopanib—Rash—Losartan—type 2 diabetes mellitus	4.61e-05	0.00029	CcSEcCtD
Pazopanib—Dermatitis—Losartan—type 2 diabetes mellitus	4.61e-05	0.00029	CcSEcCtD
Pazopanib—Headache—Losartan—type 2 diabetes mellitus	4.58e-05	0.000288	CcSEcCtD
Pazopanib—Asthenia—Ramipril—type 2 diabetes mellitus	4.5e-05	0.000283	CcSEcCtD
Pazopanib—Pruritus—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000279	CcSEcCtD
Pazopanib—Nausea—Losartan—type 2 diabetes mellitus	4.34e-05	0.000273	CcSEcCtD
Pazopanib—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.29e-05	0.00027	CcSEcCtD
Pazopanib—Dizziness—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000261	CcSEcCtD
Pazopanib—Vomiting—Ramipril—type 2 diabetes mellitus	3.99e-05	0.000251	CcSEcCtD
Pazopanib—Rash—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000249	CcSEcCtD
Pazopanib—Dermatitis—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000249	CcSEcCtD
Pazopanib—Headache—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000247	CcSEcCtD
Pazopanib—Nausea—Ramipril—type 2 diabetes mellitus	3.73e-05	0.000234	CcSEcCtD
Pazopanib—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	1.39e-06	9.76e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—SRC—type 2 diabetes mellitus	1.39e-06	9.76e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	1.39e-06	9.73e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	1.39e-06	9.71e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.37e-06	9.64e-06	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—type 2 diabetes mellitus	1.37e-06	9.61e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	1.37e-06	9.58e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.37e-06	9.57e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.36e-06	9.56e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.36e-06	9.53e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.36e-06	9.5e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.35e-06	9.49e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.35e-06	9.47e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.34e-06	9.41e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.34e-06	9.4e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.34e-06	9.39e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—SRC—type 2 diabetes mellitus	1.34e-06	9.39e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.34e-06	9.37e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.33e-06	9.35e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.33e-06	9.35e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.33e-06	9.3e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.32e-06	9.28e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—SRC—type 2 diabetes mellitus	1.32e-06	9.22e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.31e-06	9.19e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.31e-06	9.18e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.31e-06	9.16e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.3e-06	9.14e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.3e-06	9.13e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—type 2 diabetes mellitus	1.3e-06	9.12e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—type 2 diabetes mellitus	1.3e-06	9.09e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.29e-06	9.04e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—type 2 diabetes mellitus	1.29e-06	9.03e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.29e-06	9.03e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.29e-06	9.02e-06	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—AKT1—type 2 diabetes mellitus	1.29e-06	9.02e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—SRC—type 2 diabetes mellitus	1.29e-06	9.01e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.28e-06	9e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.28e-06	8.98e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.27e-06	8.93e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.27e-06	8.91e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—type 2 diabetes mellitus	1.27e-06	8.87e-06	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—type 2 diabetes mellitus	1.26e-06	8.86e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.26e-06	8.84e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.26e-06	8.81e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.26e-06	8.81e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.26e-06	8.81e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.26e-06	8.81e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.26e-06	8.8e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.25e-06	8.79e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.25e-06	8.77e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.25e-06	8.76e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.25e-06	8.75e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.25e-06	8.73e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.24e-06	8.67e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	1.23e-06	8.66e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.23e-06	8.66e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.23e-06	8.65e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.23e-06	8.64e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.23e-06	8.63e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.23e-06	8.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.23e-06	8.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.23e-06	8.59e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—type 2 diabetes mellitus	1.22e-06	8.55e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.22e-06	8.54e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.22e-06	8.53e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.22e-06	8.53e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.22e-06	8.53e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.22e-06	8.52e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.21e-06	8.51e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.21e-06	8.5e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.21e-06	8.48e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.2e-06	8.44e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—type 2 diabetes mellitus	1.2e-06	8.42e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—type 2 diabetes mellitus	1.2e-06	8.41e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.2e-06	8.4e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	1.2e-06	8.4e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.2e-06	8.39e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	1.2e-06	8.39e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.2e-06	8.38e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1.19e-06	8.36e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.19e-06	8.35e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—type 2 diabetes mellitus	1.19e-06	8.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.19e-06	8.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.18e-06	8.3e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.18e-06	8.29e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.18e-06	8.26e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	8.24e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.17e-06	8.23e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.17e-06	8.22e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	1.17e-06	8.22e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	1.17e-06	8.19e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	1.17e-06	8.19e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—type 2 diabetes mellitus	1.17e-06	8.18e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.17e-06	8.17e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.15e-06	8.09e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.15e-06	8.08e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.15e-06	8.08e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—type 2 diabetes mellitus	1.15e-06	8.05e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	1.15e-06	8.03e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—type 2 diabetes mellitus	1.14e-06	8.02e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.14e-06	8.02e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.14e-06	8.01e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.14e-06	7.98e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—type 2 diabetes mellitus	1.13e-06	7.9e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	1.12e-06	7.86e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.12e-06	7.85e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.12e-06	7.82e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.12e-06	7.82e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.11e-06	7.8e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—type 2 diabetes mellitus	1.11e-06	7.76e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	1.1e-06	7.74e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.1e-06	7.7e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.1e-06	7.7e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.1e-06	7.7e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	1.1e-06	7.7e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	7.67e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.09e-06	7.66e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.09e-06	7.66e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	7.65e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.09e-06	7.64e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.09e-06	7.62e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.08e-06	7.58e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	1.08e-06	7.56e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.08e-06	7.56e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	1.08e-06	7.56e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.07e-06	7.52e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.07e-06	7.52e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.07e-06	7.5e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.07e-06	7.5e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	1.06e-06	7.46e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.06e-06	7.46e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	1.06e-06	7.43e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—type 2 diabetes mellitus	1.06e-06	7.4e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.05e-06	7.39e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.05e-06	7.33e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	1.05e-06	7.33e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.04e-06	7.28e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.03e-06	7.24e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.03e-06	7.22e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.02e-06	7.16e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.02e-06	7.13e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	1.02e-06	7.13e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	1.01e-06	7.11e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.01e-06	7.08e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.01e-06	7.05e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.01e-06	7.05e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.01e-06	7.05e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1e-06	7.03e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	9.98e-07	6.99e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	9.95e-07	6.98e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	9.94e-07	6.97e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	9.94e-07	6.97e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	9.87e-07	6.92e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.83e-07	6.89e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.82e-07	6.88e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	9.79e-07	6.86e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.76e-07	6.84e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	9.69e-07	6.79e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.66e-07	6.77e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.63e-07	6.75e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	9.62e-07	6.74e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	9.59e-07	6.72e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	9.53e-07	6.68e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	9.53e-07	6.68e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	9.49e-07	6.65e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	9.48e-07	6.64e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	9.45e-07	6.63e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—type 2 diabetes mellitus	9.38e-07	6.57e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	9.21e-07	6.45e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	9.15e-07	6.41e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	9.09e-07	6.37e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—type 2 diabetes mellitus	9.02e-07	6.32e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	9e-07	6.31e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	8.86e-07	6.21e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	8.86e-07	6.21e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.77e-07	6.15e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	8.75e-07	6.13e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	8.75e-07	6.13e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	8.72e-07	6.12e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	8.69e-07	6.09e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—type 2 diabetes mellitus	8.66e-07	6.07e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—type 2 diabetes mellitus	8.65e-07	6.06e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	8.56e-07	6e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—type 2 diabetes mellitus	8.41e-07	5.89e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	8.39e-07	5.88e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	8.35e-07	5.85e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.32e-07	5.83e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	8.29e-07	5.81e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	8.21e-07	5.76e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	8.21e-07	5.76e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	8.19e-07	5.74e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	8.18e-07	5.73e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.17e-07	5.73e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	8.15e-07	5.71e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	8.12e-07	5.69e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	8.07e-07	5.66e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.05e-07	5.64e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	8.03e-07	5.63e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	8e-07	5.61e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—type 2 diabetes mellitus	7.99e-07	5.6e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	7.97e-07	5.59e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.89e-07	5.53e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	7.83e-07	5.49e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.76e-07	5.44e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.74e-07	5.42e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	7.64e-07	5.35e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	7.62e-07	5.34e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	7.62e-07	5.34e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	7.62e-07	5.34e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	7.56e-07	5.3e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	7.51e-07	5.26e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	7.48e-07	5.24e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	7.4e-07	5.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	7.32e-07	5.13e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	7.3e-07	5.11e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	7.18e-07	5.03e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	7.18e-07	5.03e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	7.11e-07	4.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	7.07e-07	4.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	7.02e-07	4.92e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	7e-07	4.91e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	6.97e-07	4.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.97e-07	4.89e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	6.94e-07	4.86e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.82e-07	4.78e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	6.73e-07	4.72e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	6.61e-07	4.63e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	6.57e-07	4.61e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	6.48e-07	4.54e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	6.4e-07	4.48e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	6.36e-07	4.46e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	6.29e-07	4.41e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	6.27e-07	4.39e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	6.2e-07	4.34e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	6.09e-07	4.27e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	6.09e-07	4.27e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	6.06e-07	4.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.59e-07	3.92e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	5.57e-07	3.9e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	5.46e-07	3.83e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	5.36e-07	3.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	4.91e-07	3.44e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4.7e-07	3.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4.7e-07	3.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	4.3e-07	3.01e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	4.02e-07	2.82e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.5e-07	2.46e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.3e-07	2.31e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	2.8e-07	1.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.16e-07	1.51e-06	CbGpPWpGaD
